JAKARTA - PT Diagnos Laboratorium Utama Tbk (DGNS), a clinical laboratory service provider under Bundamedik Group, is anticipating the decline in its revenue and profit post COVID-19 crisis. The management then admitted that this year, the company will only focus on improving existing outlets without planning any more expansion plans.

Until the end of the first quarter of 2023, COVID-19 tests did no longer contribute to DGNS's revenue as the pandemic ends. "Our future prospects lie on non-COVID tests, including genomic testing, as well as performances in our outlets," said Fergus Richard, Director of Finance, IT, Procurement, and Corplan of DGNS, during the Public Expose today (19/6). Along with those strategies, the contribution of genomic testing to DGNS's revenue in Q1 2023 also increased to 11.2% from the previous 2.9% in Q1 2022.

Dessy Lapagu, Head of Corporate Finance & Investor Relation of DGNS, also confirms that this year, the company will only focus on reinforcing existing outlets. "Financially, within the next three quarters of this year, we will focus on maintaining our gross profit margin to be around 52%-53%, as we see in late 2022," she continued further.

In 2023, Richard said that DGNS has prepared capital expenditure of IDR 35 billion, IDR 7 billion of which will be spent on acquiring medical equipment and improving the quality of currently existing outlets. Meanwhile, another IDR 25 billion will be focused for central laboratory of DGNS. (ZH)